NEW YORK, May 14, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that the Company's major investment company AXIM® Biotechnologies, Inc. (OTC: AXIM) ("AXIM"), a world leader in cannabinoid research and development, has filed a provisional
"As a company of firsts, Medical Marijuana, Inc. is proud to support AXIM as it files this patent application for the first-ever cannabis-based gum formulated to treat the symptoms of migraines," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Studies have estimated that migraines affect roughly 38 million people in the U.S. and the market currently lacks an effective natural treatment option for those people."
AXIM plans to formulate a chewing gum under this invention that contains feverfew extract, cannabidiol (CBD) and/or cannabigerol (CBG) for treatment of symptoms that often accompany migraines, such as headache, pain, nausea, and light sensitivity. Feverfew has been proven to relieve and prevent symptoms of migraines.
The new formulation will be delivered through AXIM's proprietary sustained-release chewing gum delivery technology to release active ingredients in a controlled manner into the oral cavity.
"AXIM is best known for its patent on chewing gum containing cannabinoids and our flagship CBD chewing gum product, CanChew+," said AXIM CEO John W. Huemoeller II. "With this patent application and AXIM's current cannabis chewing gum products currently in development, we plan to bring a variety of treatment options to the market."
According to Grand View Research, Inc., the global migraine treatment market size is expected to reach $7.8 billion by 2025.
To learn more about Medical Marijuana, Inc., visit https://www.medicalmarijuanainc.com/.
To learn more about AXIM® Biotechnologies, Inc., visit http://aximbiotech.com/.
About Medical Marijuana, Inc.We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
About AXIM® BiotechnologiesAXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.
AXIM's flagship products include MedChew® with dronabinol, which is planned to undergo a bioequivalence study to fast track through FDA as an alternative to approved Marinol; MedChew® RL, which is planned to undergo clinical trials for treatment of restless leg syndrome; and MedChew® Rx, a combination cannabidiol (CBD)/tetrahydrocannabinol (THC) functional, controlled-release chewing gum that is planned to undergo clinical trials for the treatment of pain and spasticity associated with Multiple Sclerosis (MS). For more information, please visit www.AXIMBiotech.com.
Public Relations Contact:Andrew HardChief Executive OfficerCMW MediaP. email@example.com
Corporate Contact Info:North American Address:45 Rockefeller Plaza, 20th Fl.New York, NY 10111, USAP. 844 294 6246
European Address:Industrieweg 40, Unit B43401 MA IJsselsteinNetherlands
FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSUREAXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
View original content:http://www.prnewswire.com/news-releases/medical-marijuana-inc-major-investment-company-axim-biotechnologies-files-new-us-provisional-patent-for-cannabis-gum-as-a-treatment-for-migraine-symptoms-300849536.html
SOURCE Medical Marijuana, Inc.
Subscribe to our Free Newsletters!